Roche wins first-line approval for PI3K inhibitor combo in breast cancer
The US Food and Drug Administration (FDA) has approved Roche’s Itovebi (inavolisib) in combination with Pfizer’s Ibrance (palbociclib) and AstraZeneca’s…
All articles by Phalguni Deswal
Phalguni Deswal
@Phalguni_GD
Phalguni Deswal is reporter in the healthcare and pharmaceutical sector. With a background in medicine, Phalguni has experience working in the Indian healthcare sector. Phalguni is interested in metabolic drug therapies, digital health technologies, and drug development.
-
-
Biogen scores breakthrough status for anti-rejection transplant medication
The US Food and Drug Administration (FDA) has granted a breakthrough therapy designation for its monoclonal antibody felzartamab as a…
-
MSD ventures into fibroblast therapies with $1.9bn deal with Mestag
MSD (Merck & Co) has signed a license and collaboration agreement with Mestag Therapeutics to develop new fibroblast therapies for…
-
Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status
Boehringer Ingelheim has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for survodutide as a…
-
Oncolytics targets accelerated approval for oncolytic virus therapy
Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep, with plans to start a registrational Phase II…
-
FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
The US Food and Drug Administration (FDA) has lifted the partial clinical hold on Avidity Biosciences’ investigational drug, delpacibart etedesiran…
-
Resolution scores $83m to develop macrophage cell therapies
Resolution Therapeutics has raised £63.5m ($83.3m) in a Series B financing round to develop its macrophage cell therapies. The UK-based…
-
Shattuck Labs stock craters following pipeline and job cuts
Shattuck Labs has dropped by nearly 45% after it announced plans to reduce its headcount and discontinue its lead cancer…
-
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials
Biomea Fusion’s stock is on the up after the company plans to resume two clinical trials evaluating its therapy for…
-
Union plans Phase III trial for atopic dermatitis after Phase IIb win
Union Therapeutics is looking to advance its PDE4 inhibitor, orismilast, into a Phase III clinical trial for atopic dermatitis (AD)…